Skip to main content
A#2531 @AlisaMueller
CRISPR deletion of fibroblasts, gave cytokine activation to mimic inflamm
Are there gene depletion

Eric Dein ericdeinmd

1 year 10 months ago
A#2531 @AlisaMueller CRISPR deletion of fibroblasts, gave cytokine activation to mimic inflamm Are there gene depletions that affect inflamm pathways? 👉SIX1 reduces inflamm potentiation 👉NFIL3 deletion promotes inflamm, degradation @RheumNow #ACR24 https://t.co/Nqghb5UaBR
A#2532
Pre-existing AID for immunoRx?
Excluded from trials
4 prior studies showed no diff in mortality w AID
Propensity-

Eric Dein ericdeinmd

1 year 10 months ago
A#2532 Pre-existing AID for immunoRx? Excluded from trials 4 prior studies showed no diff in mortality w AID Propensity-matched cohort study Followed median 250 days Hazard ratio: 1.07 (unmatched), 0.97 (matched) - no diff. Mortality about 40% in grps @RheumNow #ACR24 https://t.co/zyVCPts6s6
Imaging in TAK Diagnosis
@KQuinnRheum @RheumNow

⭐ Take homes ⭐

👉location of renal artery stenosis (RAS) key t

Patricia Harkins DrTrishHarkins

1 year 10 months ago
Imaging in TAK Diagnosis @KQuinnRheum @RheumNow ⭐ Take homes ⭐ 👉location of renal artery stenosis (RAS) key to making Dx with proximal RAS in TAK 👉FDG PET -focal uptake in TAK vs diffuse in GCA 👉MRI good surrogate for disease activity where PET unavailable #ACR24 https://t.co/UWxTAZScIt
Mental health, sex, and comorbidities are key factors in determining recalcitrant psoriatic arthritis (PsA).
Key finding

Antoni Chan MD (Prof) synovialjoints

1 year 10 months ago
Mental health, sex, and comorbidities are key factors in determining recalcitrant psoriatic arthritis (PsA). Key findings: - 21.7% of patients required ≥4 biologic/targeted synthetic DMARDs. - Female patients and those with depression were more likely to be recalcitrant. - No… https://t.co/I9YYoRnLwh https://t.co/VtnPceVLOZ
the predictive value of a positive ANA test—especially in the absence of other clinical symptoms—remains a challenge. A positive test often leads to further testing, yet it does not necessarily indicate whether a patient truly has an underlying autoimmune disease. The development of AI and machine learning algorithms presents an opportunity to interpret autoantibody tests and predict autoimmune diseases. Here are three studies looking at this
Treating SpA
#ACR24 - Featured Industry Presentations

Many of the great presentations for this meeting come from industry sponsored

Dr. John Cush RheumNow

1 year 10 months ago
#ACR24 - Featured Industry Presentations Many of the great presentations for this meeting come from industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.… https://t.co/I6LMQ5xMUx https://t.co/UzTeqWUSdo
The precise mechanism of action of GIOP is not known. Decrease in osteocyte LCN is observed. Abstr#2528 @RheumNow #ACR24

Antoni Chan MD (Prof) synovialjoints

1 year 10 months ago
The precise mechanism of action of GIOP is not known. Decrease in osteocyte LCN is observed. Abstr#2528 @RheumNow #ACR24 https://t.co/fazUUy03fQ
In earlier studies of Vit D, there were conflicting evidence as to whether it reduced or increased the risk of RA and #S

sheila RHEUMarampa

1 year 10 months ago
In earlier studies of Vit D, there were conflicting evidence as to whether it reduced or increased the risk of RA and #SLE @RheumNow #ACR24 @rheumarhyme https://t.co/PvjjmhHaOd
A Bayesian Network Meta-analysis Phase II/III/IV, placebo-controlled, randomised clinical trials and long-term extension

Antoni Chan MD (Prof) synovialjoints

1 year 10 months ago
A Bayesian Network Meta-analysis Phase II/III/IV, placebo-controlled, randomised clinical trials and long-term extension studies of JAKi and TNFi, in adults with RA, PsO, PsA, axial spondyloarthritis axSpA and IBD showed the following: - TNFi was associated with a significantly… https://t.co/FWHgemEAvG https://t.co/3D0nldwmwA
Nipocalimab, an anti-neonatal Fc receptor (FcRn) mAb, reduces circulating IgG including specific autoantibodies (AAb), b

Antoni Chan MD (Prof) synovialjoints

1 year 10 months ago
Nipocalimab, an anti-neonatal Fc receptor (FcRn) mAb, reduces circulating IgG including specific autoantibodies (AAb), by selectively blocking IgG–FcRn interactions. DAHLIAS, the first study of a FcRn blocker in SjD, showed that nipocalimab led to significant improvement vs PBO… https://t.co/zl1tEsEMAj https://t.co/qrkOD2Ccc3
A#2527 DAHLIAS, P2Nipocalimab: Anti-FcRn Ab in Ro+ SjDIV 5 or 15 mg/kgPrim Endpt: 15 mg/kg has ClinESSDAI at w24 -6.4

Eric Dein ericdeinmd

1 year 10 months ago

A#2527 DAHLIAS, P2 Nipocalimab: Anti-FcRn Ab in Ro+ SjD IV 5 or 15 mg/kg Prim Endpt: 15 mg/kg has ClinESSDAI at w24 -6.4 v -3.7 PBO p=0.002 Improv dryness, fatigue, pain Better unstim salivary flow Best response in higher Ab titer pts Safety data good #ACRBest #ACR24 @RheumNow https://t.co/O7zahPul66

×